Key Takeaways
- Profit surge despite soft API pricing: PAT jumped 34% YoY in Q2 and 67% in H1, driven by medical devices growth and expense control, even as API revenue fell 13% on a 28% price decline.
- Volume-price divergence in API: API volumes rose 25% but realizations dropped 28%, a deliberate pass-through of lower raw material costs that management expects to firm up as the market stabilizes.
- Medical devices is the growth engine: The segment grew 41% in Q2 and 44% in H1, with glucometer strips up 42% and BP monitors up 52%, approaching COVID-era levels.
- Formulation business restructured for focus: The formulation business was moved to a separate subsidiary, Morepen RX Limited, in August 2023, and management is expanding the team and capacity to accelerate historically slow 10% CAGR growth.
- What to watch next quarter: Whether formulation sales begin their promised uptick, any recovery in the lost Loratadine tender, and the pace of customer acquisition for newly launched molecules Tafamidis and Ticagrelor.
API Business: Volume Growth, Margin Pressure
- Volume up, price down: API revenue declined 13% YoY but volume grew 25% because sales realization dropped 28%. Last year, raw material cost increases forced price hikes; now costs are softening and the benefit is being passed to customers.
- Export push over domestic: The company deliberately avoided domestic API sales and pushed more toward exports, causing the domestic API market to decline versus last year.
- Loratadine drag: Loratadine, a major US product, saw H1 sales fall from ₹130 crores to ₹69 crores because the customer did not win a government supply tender this year. Loratadine carried 60%+ margins while replacement products carry only 40%, dragging the API average margin to 40% and impacting both top and bottom line.
- Capacity constraints biting: The company is falling short of capacity, with customers asking for more material even at lower prices. A new production block, P11, has been started to address this.
- New molecule pipeline: Management emphasized the focus is on new, high-gross molecules, not traditional APIs like paracetamol or amoxicillin. New DMFs were filed for Desloratadine, Loratadine, Edoxaban, Rivaroxaban, Montelukast, Linagliptin, Metagliptin, and Saxagliptin, and new patents were secured for Rivaroxaban, Fexofenadine, and Dapagliflozin.
- Product-level bright spots: Fexofenadine grew 413%, Olmesartan 172%, Rosuvastatin 26%, and Atorvastatin 12%, partially offsetting the Loratadine decline.
- Geography shifts: The US market share rose due to the new Fexofenadine approval, while Europe was disturbed by the Russia situation and Asia declined due to the China factor. India, South America, and the US were the three major markets that grew.
Sushil Suri: "when we say API, we are not talking of traditional APIs, we are not talking of paracetamol, and ceflexane, and amoxicillin in the world. We are talking new molecules, with high-gross molecules"
Medical Devices: The Standout Performer
- Segment momentum: Medical devices grew 41% in Q2 and 44% in H1, accelerating from an already strong 25% CAGR. QoQ growth was 16%.
- Glucometer ecosystem: The company has built a base of 1.06 crore customers buying strips regularly, with 140 crore strips sold and 0.13 crore meters sold in the first half. Glucometer revenue grew 42% in H1. Meters are placed at a discount to lock in recurring strip purchases, though the company cannot distinguish old versus new customer strip revenue because chemists do not share that data.
- BP monitors resurgence: BP monitor sales grew 52% in H1, reaching ₹44 crores, approaching the COVID-era peak of ₹84 crores.
- Subsidiary plan: Management plans to move the medical devices business into a separate subsidiary, mirroring the formulation restructuring.
- Growth expectation: Management indicated that even 30-35% annual growth in medical devices would be considered good, suggesting a tempered outlook from the current 44% pace.
Formulation & OTC: Restructuring for a Turnaround
- Formulation moved to subsidiary: The formulation business was transferred to Morepen RX Limited on August 15, 2023, meaning half of Q2 sales were booked in the parent and half in the subsidiary. OTC products (Dr. Morepen, Burnol, Lemolate, ORS) were already housed there.
- Slow legacy growth: Formulation has historically grown at a 10% CAGR, well below the 18% for API and 29% for medical devices. Q2 growth was 16% YoY and 4% QoQ.
- Segment mix shifting: Antibiotics make up 24% of the formulation mix, vitamins only 1%, while gastro products grew 52% and other small products grew 135%.
- Branded generic drag: Within the three formulation segments (Rx, branded generic, generic), the branded generic business has no top line and generally faces losses, offsetting profits from API and devices.
- OTC kept on a leash: Dr. Morepen OTC was flat in H1 (₹49 crores to ₹48 crores) with 9% QoQ growth. Management is deliberately keeping investment shy because online customer acquisition costs are high and it is "easy to burn money." Burnol is focused only on burns, a small category that limits growth. Online sales were strategically reduced by 31%.
- Dr. Morepen IPO on hold: Dr. Morepen is an independent company and an IPO candidate, but management stated it cannot go to market until the business reaches ₹200 to ₹300 crores, from the current stable ₹100 crores. The timeline is another two to three years.
Sushil Suri: "It's a strategic call. It's easy to burn money and throw money, but naturally we don't have our so called investor's money to burn like our other startups are doing. We are a bit conservative"
Margins & Cost Structure
- EBITDA improvement: EBITDA rose 24% in Q2 and 44% in H1, with good expense control contributing. Last year's EBITDA margins were around 6.5%, now at approximately 8%, a net improvement of roughly 2 percentage points.
- Employee cost leverage: Employee cost as a percentage of revenue was 10.9% last year and 10.5% on an H1 basis. Management expects this ratio to decline as revenue grows because the same headcount will generate more output.
- Formulation losses offsetting gains: Losses in the branded generic formulation business are offsetting profits from the API and medical devices segments, creating a drag on consolidated margins.
- Two-digit EBITDA target: Management expects EBITDA margins to reach double digits in the next financial year, with the mechanism being that expenses are already covered and any revenue increase will flow to the bottom line.
People, Culture & Systems
- Senior leadership hires: The company onboarded several senior executives during the quarter, including a Chief Growth Officer (Lalit Baregama, 20 years at Cadila/VIMTA Labs), a manufacturing lead from Centrient/DSM Sinochem, territory heads from Jubilant/Sun Pharma/Biocon, a Senior AVP for formulation (29 years at Netco/Cadila/Torrent), and a National Sales Manager for Rx.
- Internal engagement initiatives: A weekly in-house talk show called "Bubble Chat" was started six months ago and has moved to monthly live streaming. A masterclass with Dr. Ram Charan was held on October 3rd with 150 attendees. The company won a "best company to work for" award from Tradeflock in 2023.
- Technology adoption: Slack was implemented for fast, regulated, and secure internal communication. A consumer-facing Salesforce CRM was activated.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin target | Reach double-digit EBITDA margins | Next financial year (FY25) |
| Revenue growth | Maintain 15-20% CAGR (20% outside, 15% bare minimum) | Ongoing |
| Formulation revenue improvement | Formulation sales to start increasing, improving bottom lines | From next quarter (Q4 FY24) onward |
| Loratadine tender recovery | Customer may win a government supply tender | Late this year or next year |
| Dr. Morepen IPO readiness | Business must reach ₹200-300 crores before IPO (currently ~₹100 crores) | Two to three years |
| API capex funding | ₹125 crores API capex, preferring debt over equity | Not specified |
| Medical devices capex | ₹50-75 crores funded from internal cash flows | Not specified |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | ₹425 cr, +5% YoY |
| H1 FY24 revenue | ₹828 cr, +17% YoY |
| EBITDA | +24% YoY |
| H1 FY24 EBITDA | +44% YoY |
| Profit before tax | +29% YoY |
| Profit after tax | ₹21.26 cr, +34% YoY |
| H1 FY24 PAT | ₹36 cr, +67% YoY |
| EBITDA margin | ~8%, up from ~6.5% last year |
| API segment revenue | ₹212 cr, +5% QoQ; volume up 25% but realization down 28% |
| API segment H1 revenue | ₹415 cr, +5% YoY |
| Medical devices revenue growth | +41% YoY in Q2, +44% in H1 |
| Medical devices H1 revenue | ₹248 cr, on track to cross ₹400 cr for full year |
| Glucometer H1 revenue | ₹195 cr, +42% YoY |
| Glucometer active customer base | 1.06 cr |
| BP monitors H1 growth | +52% YoY |
| Formulation business growth | +16% YoY in Q2, +12% in H1 |
| Dr. Morepen OTC H1 revenue | ₹48 cr, flat YoY |
| Domestic revenue growth | +26% YoY in Q2, +31% in H1 |
| API division EBITDA margin | 14% to 15% (before corporate expenses) |
| Medical devices EBITDA margin | 12% to 13% (before corporate expenses) |
| Capex plan, API | ₹125 cr |
| Capex plan, medical devices | ₹50 to ₹75 cr |
| Employee count | 3,000+ |
| R&D team size | 36 scientists |
| US DMFs filed | 26 |
| Patents held | 543 |
| New products launched, last 3 years | 41 |